Psych Vivas · General adult psychiatry — anxiety disorders
Social anxiety disorder — structured clinical viva
Fellowship viva covering chronic SAD, alcohol safety behaviour, inadequate prior SSRI trials, Clark/Wells CBT targets, and evidence-based medication including maintenance and specialist MAOI context.
On this page & tools
Target exams
Interpretation
Reveal interpretation
This is generalised social anxiety disorder (interactional and performance situations) with alcohol as a safety behaviour and inadequate prior antidepressant trials (stopped within 10 days — not therapeutic dose/duration). The belief "I already know I am awkward" is a treatment target (distorted self-image / certainty without behavioural experiments), not a reason to abandon CBT. Do not escalate long-term benzodiazepines as the primary plan.[1][4][5]
Formulation. Vulnerability (possible behavioural inhibition/temperament), maintaining factors (self-focused attention, safety behaviours including alcohol, post-event processing, avoidance of meetings), precipitants (workplace demands), and iatrogenic history of aborted SSRI trials without activation management.[1]
SSRI re-challenge strategy. Explain early activation; start low (e.g. sertraline 25 mg), frequent early review, short-term non-escalating support, parallel CBT engagement work. Prior "failure" at 10 days is not pharmacological non-response.[3][5]
CBT sales pitch without collusion. Validate distress; introduce experiments testing whether others notice blushing as much as feared; attention training; video feedback; drop alcohol-as-safety-behaviour experiments with medical support if dependence risk high.[1][4]
Specialist ladder. If true non-response after adequate SSRI/SNRI and quality CBT: switch class, combination, refractory pathway; phenelzine has landmark comparative efficacy versus CBGT but requires specialist MAOI counselling (diet, interactions, washout).[2][5]
Maintenance. After response, continue medication for a substantial period — sertraline continuation reduces relapse versus placebo substitution in responders.[6]
Key points
Escalating viva questions
- Reproduce DSM-5-TR social anxiety criteria and the performance-only specifier.
- How do you discriminate SAD from avoidant personality disorder and ASD?
- Name three CBT ingredients for SAD with rationale.
- Give a first-line drug with start dose, therapeutic range and early monitoring.
- What did Heimberg 1998 and Walker 2000 contribute? [2][3][6]
References
- [1]Stein MB, Stein DJ Social anxiety disorder Lancet, 2008.PMID 18374843
- [2]Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome Arch Gen Psychiatry, 1998.PMID 9862558
- [3]Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia Am J Psychiatry, 2001.PMID 11156811
- [4]Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis Lancet Psychiatry, 2014.PMID 26361000
- [5]Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders BMC Psychiatry, 2014.PMID 25081580
- [6]Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment J Clin Psychopharmacol, 2000.PMID 11106135